Deltex Medical Group PLC Investor Event

TIDMDEMG

Deltex Medical Group PLC

10 May 2018

10 May 2018

Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")

Investor Event

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), announces that it will be hosting an investor event on 22 May 2018 following the publication of its full year results for the twelve months ended 31 December 2017.

The event will be held at Davy's at Woolgate Bar and Brasserie, Woolgate Exchange, 25 Basinghall Street, London, EC2V 5HA from 18:00 and will take the form of a Company presentation followed by a Q&A session. The presentation for the event will also be made available on the Company's website.

Potential investors and shareholders who wish to attend the event should register their interest with Florence Chandler at IFC Advisory Ltd on [e-mail] or on 020 3934 6636.

For further information, please contact:

 
 Deltex Medical Group plc                 01243 774 837 
 Nigel Keen, Chairman                     [e-mail] 
 Ewan Phillips, Chief Executive 
 Jonathan Shaw, Group Finance Director 
 
 
 Arden Partners plc (Nominated Adviser 
  & Broker)                               020 7614 5900 
 Chris Hardie 
 Ciaran Walsh 
 
 
 Turner Pope Investments (TPI) Ltd 
  (Joint Broker)                          0203 621 4120 
 Andy Thacker                             [e-mail] 
 
 
 IFC Advisory Ltd (Financial Public 
  Relations)                              0203 934 6630 
 Tim Metcalfe 
 Graham Herring 
 Heather Armstrong 
 
 

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhancedhaemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.

Deltex Medical's CardioQ-ODM+ platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis uses peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamicallystable patients.

Company goal

Haemodynamic management is now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Company aims to provide clinicians with a single platform, a 'haemodynamicworkstation', which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition and skill and expertise of the user. Doing this will enable the Company to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAFKCDBABKDAPK

(END) Dow Jones Newswires

May 10, 2018 02:01 ET (06:01 GMT)